Ocular Therapeutix (OCUL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.87, -6.91% vs the prior close of $7.38.
- Volume 2.76M shares, 0.9x its 50-day average.
- New SEC filings: 8-K (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
OCUL slides 6.9% to $6.87, a 52-week low. Closed at $6.87, -6.91% vs the prior close of $7.38. Day range $6.85–$7.39, opened at $7.36.
OCUL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — OCUL slides 6.9% to $6.87, a 52-week low
- Closed at $6.87, -6.91% vs the prior close of $7.38. Day range $6.85–$7.39, opened at $7.36.
- Volume was 2.76M shares, 0.9x its 50-day average of 3.14M.
- Price is -27.9% vs its 50-day average ($9.53) and -26.5% vs its 200-day average ($9.35).
- 52-week range $6.23–$16.44; today's close sits at 6% of that range, 58.2% below the 52-week high.
Oct 15, 2026 — OCUL rises 2.5% to $7.38
- Closed at $7.38, +2.50% vs the prior close of $7.20. Day range $7.23–$7.47, opened at $7.29.
- Volume was 3.25M shares, 1.0x its 50-day average of 3.11M.
- Price is -22.8% vs its 50-day average ($9.56) and -21.3% vs its 200-day average ($9.37).
- 52-week range $6.23–$16.44; today's close sits at 11% of that range, 55.1% below the 52-week high.
Oct 14, 2026 — OCUL dips 0.6% to $7.20
- Closed at $7.20, -0.55% vs the prior close of $7.24. Day range $7.07–$7.30, opened at $7.14.
- Volume was 2.21M shares, 0.7x its 50-day average of 3.11M.
- Price is -24.9% vs its 50-day average ($9.59) and -23.4% vs its 200-day average ($9.40).
- 52-week range $6.23–$16.44; today's close sits at 10% of that range, 56.2% below the 52-week high.
Oct 13, 2026 — OCUL slides 4.2% to $7.24
- Closed at $7.24, -4.23% vs the prior close of $7.56. Day range $7.20–$7.61, opened at $7.55.
- Volume was 3.22M shares, 1.0x its 50-day average of 3.11M.
- Price is -24.7% vs its 50-day average ($9.61) and -23.2% vs its 200-day average ($9.42).
- 52-week range $6.23–$16.44; today's close sits at 10% of that range, 56.0% below the 52-week high.
Oct 12, 2026 — OCUL ends flat (+0.3%) to $7.56, 3 up days in a row
- Closed at $7.56, +0.27% vs the prior close of $7.54. Day range $7.36–$7.75, opened at $7.60.
- Volume was 3.67M shares, 1.2x its 50-day average of 3.08M.
- Price is -21.6% vs its 50-day average ($9.64) and -20.0% vs its 200-day average ($9.45).
- 52-week range $6.23–$16.44; today's close sits at 13% of that range, 54.0% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — OCUL rises 0.4% to $7.54
- Closed at $7.54, +0.40% vs the prior close of $7.51. Day range $7.38–$7.68, opened at $7.49.
- Volume was 2.63M shares, 0.9x its 50-day average of 3.08M.
- Price is -21.9% vs its 50-day average ($9.65) and -20.4% vs its 200-day average ($9.48).
- 52-week range $6.23–$16.44; today's close sits at 13% of that range, 54.1% below the 52-week high.
Oct 8, 2026 — OCUL jumps 3.9% to $7.51
- Closed at $7.51, +3.87% vs the prior close of $7.23. Day range $7.06–$7.57, opened at $7.20.
- Volume was 3.90M shares, 1.3x its 50-day average of 3.04M.
- Price is -22.3% vs its 50-day average ($9.67) and -21.0% vs its 200-day average ($9.50).
- 52-week range $6.23–$16.44; today's close sits at 13% of that range, 54.3% below the 52-week high.
Oct 7, 2026 — OCUL dips 1.5% to $7.23
- Closed at $7.23, -1.50% vs the prior close of $7.34. Day range $7.19–$7.55, opened at $7.26.
- Volume was 2.93M shares, 1.0x its 50-day average of 3.03M.
- Price is -25.4% vs its 50-day average ($9.69) and -24.1% vs its 200-day average ($9.53).
- 52-week range $6.23–$16.44; today's close sits at 10% of that range, 56.0% below the 52-week high.
Oct 6, 2026 — OCUL rises 1.2% to $7.34
- Closed at $7.34, +1.24% vs the prior close of $7.25. Day range $7.13–$7.57, opened at $7.30.
- Volume was 2.81M shares, 0.9x its 50-day average of 3.00M.
- Price is -24.4% vs its 50-day average ($9.71) and -23.2% vs its 200-day average ($9.56).
- 52-week range $6.23–$16.44; today's close sits at 11% of that range, 55.4% below the 52-week high.
Oct 5, 2026 — OCUL jumps 4.2% to $7.25 on 1.9x normal volume
- Closed at $7.25, +4.17% vs the prior close of $6.96. Day range $6.79–$7.27, opened at $6.93.
- Volume was 5.62M shares, 1.9x its 50-day average of 2.91M — unusually heavy trading.
- Price is -25.5% vs its 50-day average ($9.74) and -24.4% vs its 200-day average ($9.59).
- 52-week range $6.23–$16.44; today's close sits at 10% of that range, 55.9% below the 52-week high.
Oct 2, 2026 — OCUL slides 4.5% to $6.96, a 6-month low, 3 down days in a row
- Closed at $6.96, -4.53% vs the prior close of $7.29. Day range $6.93–$7.43, opened at $7.40.
- Volume was 4.96M shares, 1.7x its 50-day average of 2.85M.
- Price is -28.7% vs its 50-day average ($9.76) and -27.7% vs its 200-day average ($9.63).
- 52-week range $6.23–$16.44; today's close sits at 7% of that range, 57.7% below the 52-week high.
- That makes 3 straight losses.
OCUL latest news & SEC filings
Every SEC filing by or about OCUL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Anderman Todd sold 11,984 shares at $7.29 (≈$87.36K) on Oct 8, 2026; now holds 140,484
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kaiser Peter sold 9,990 shares at $7.05 (≈$70.43K) on Oct 2, 2026; now holds 254,388
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Heier Jeffrey S. sold 10,869 shares at $7.05 (≈$76.63K) on Oct 2, 2026; now holds 307,457
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 3, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 3, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $13.47M (prior year $13.46M) (+0.1% vs Jun 30, 2025)
- Net income: -$78.76M (prior year -$67.81M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.35 (prior year -$0.39) (loss narrowed vs Jun 30, 2025)
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade OCUL
- Last results release: Aug 3, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 5, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Nov 2, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.73% (largest 20.7%). That is a volatile stock.
- Liquidity: about 3.89M shares (≈$26.76M) trade per day on average.
- 52-week position: $6.87 vs a range of $6.23–$16.44 (6% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Donald Notman sold 1,099 shares on Aug 31, 2026.
- Latest filings: 8-K Oct 16, 2026; 10-Q Aug 3, 2026; 8-K Aug 3, 2026.
- Share count: 219.62M shares outstanding (Jul 31, 2026), +26.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
OCUL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.36 | 7.39 | 6.85 | 6.87 | 2.76M |
| Oct 15, 2026 | 7.29 | 7.47 | 7.23 | 7.38 | 3.25M |
| Oct 14, 2026 | 7.14 | 7.30 | 7.07 | 7.20 | 2.21M |
| Oct 13, 2026 | 7.55 | 7.61 | 7.20 | 7.24 | 3.22M |
| Oct 12, 2026 | 7.60 | 7.75 | 7.36 | 7.56 | 3.67M |
| Oct 9, 2026 | 7.49 | 7.68 | 7.38 | 7.54 | 2.63M |
| Oct 8, 2026 | 7.20 | 7.57 | 7.06 | 7.51 | 3.90M |
| Oct 7, 2026 | 7.26 | 7.55 | 7.19 | 7.23 | 2.93M |
| Oct 6, 2026 | 7.30 | 7.57 | 7.13 | 7.34 | 2.81M |
| Oct 5, 2026 | 6.93 | 7.27 | 6.79 | 7.25 | 5.62M |
| Oct 2, 2026 | 7.40 | 7.43 | 6.93 | 6.96 | 4.96M |
| Oct 1, 2026 | 7.63 | 7.70 | 7.26 | 7.29 | 4.51M |
| Sep 30, 2026 | 7.88 | 8.16 | 7.63 | 7.67 | 4.56M |
| Sep 29, 2026 | 7.80 | 8.13 | 7.51 | 7.87 | 5.28M |
| Sep 28, 2026 | 9.38 | 9.38 | 7.18 | 7.66 | 15.44M |
| Sep 25, 2026 | 9.77 | 9.85 | 9.59 | 9.65 | 1.62M |
| Sep 24, 2026 | 9.94 | 9.98 | 9.60 | 9.82 | 1.86M |
| Sep 23, 2026 | 10.48 | 10.57 | 9.77 | 10.00 | 2.09M |
| Sep 22, 2026 | 10.08 | 10.61 | 10.02 | 10.50 | 2.50M |
| Sep 21, 2026 | 10.08 | 10.17 | 9.81 | 9.99 | 2.07M |
About Ocular Therapeutix
Ocular Therapeutix (OCUL) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BEDFORD, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1393434.
OCUL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Pravin Dugel | See Remarks | Aug 26, 2026 |
| Adrienne L Graves | Director | Jun 12, 2026 |
| Seung Suh Hong | Director | Jun 12, 2026 |
| Richard L Md Lindstrom | Director | Jun 12, 2026 |
| Merilee Raines | Director | Jun 12, 2026 |
| Charles M Warden | Director | Jun 12, 2026 |
| Leslie J. Williams | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Todd Anderman | Chief Legal Officer | Jan 6, 2026 |
| Pravin Dugel | See Remarks | Aug 26, 2026 |
| Jeffrey S. Heier | Chief Scientific Officer | Aug 26, 2026 |
| Peter Kaiser | Chief Development Officer | Aug 26, 2026 |
| Steve Lawrence Meyers | Chief Commercial Officer | Jan 6, 2026 |
| Sanjay Nayak | Chief Strategy Officer | Aug 26, 2026 |
| Donald Notman | Chief Operating Officer | Sep 2, 2026 |
| Jason Shand Robins | Chief Financial Officer | Jun 12, 2026 |
| David Wayne Robinson | Global CCO | Jan 26, 2026 |
| Namrata Saroj | Chief Business Officer | Jan 6, 2026 |
| Nadia Waheed | Chief Medical Officer | Jun 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 31, 2026 | Donald Notman | Sale | 1,099 | $10.24 |
| Aug 31, 2026 | Donald Notman | Sale | 1,099 | $10.24 |
| Aug 31, 2026 | Donald Notman | Sale | 1,099 | $10.24 |
| Aug 31, 2026 | Donald Notman | Sale | 1,099 | $10.24 |
| Aug 24, 2026 | Sanjay Nayak | Sale | 1,897 | $10.78 |
| Aug 24, 2026 | Sanjay Nayak | Sale | 1,897 | $10.78 |
| Aug 24, 2026 | Sanjay Nayak | Sale | 1,897 | $10.78 |
| Aug 24, 2026 | Sanjay Nayak | Sale | 1,897 | $10.78 |
| Aug 24, 2026 | Peter Kaiser | Sale | 3,035 | $10.77 |
| Aug 24, 2026 | Peter Kaiser | Sale | 3,035 | $10.77 |
| Aug 24, 2026 | Peter Kaiser | Sale | 3,035 | $10.77 |
| Aug 24, 2026 | Peter Kaiser | Sale | 3,035 | $10.77 |
| Aug 24, 2026 | Pravin Dugel | Sale | 21,649 | $10.77 |
| Aug 24, 2026 | Pravin Dugel | Sale | 21,649 | $10.77 |
| Aug 24, 2026 | Pravin Dugel | Sale | 21,649 | $10.77 |
OCUL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $51.95M | $-265.94M | -1.42 | $-204.88M |
| Dec 31, 2024 | $63.72M | $-193.51M | -1.22 | $-134.68M |
| Dec 31, 2023 | $58.44M | $-80.74M | -1.02 | $-70.23M |
| Dec 31, 2022 | $51.49M | $-71.04M | -0.97 | $-59.60M |
| Dec 31, 2021 | $43.52M | $-6.55M | -0.98 | $-65.55M |
Latest balance sheet: total assets $671.32M, total liabilities $151.28M, cash $598.64M (as of Jun 30, 2026).
OCUL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 3, 2026 | 8-K Item 2.02 (results) | $8.40 |
| May 5, 2026 | 8-K Item 2.02 (results) | $9.71 |
| Feb 5, 2026 | 8-K Item 2.02 (results) | $8.91 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $10.90 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $12.00 |
| May 5, 2025 | 8-K Item 2.02 (results) | $7.73 |
| Mar 3, 2025 | 8-K Item 2.02 (results) | $5.93 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $9.92 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
| Feb 22, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on OCUL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.